Company profile
Lexington Biosciences, Inc.
OTC: LXGTF · Healthcare · Medical - Specialties
Canadian filerHQ Vancouver, BCReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 43
v0.1 · 5/100 weight · pillars only
↑ workforce scale, disclosure history · ↓ market scale, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$131.4k
Employees
543
as of 2026-08-30
Market cap
$379
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2023
Net income-$131.4k-177.4k CAD2023
Operating income-$117.1k-158.0k CAD2023
Total assets$00 CAD2023
Liabilities$747.6k988.8k CAD2023
Equity-$747.6k-988.8k CAD2023
Revenue trend
FY2017 – FY2023 · USD
FY17
FY18
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Lexington Biosciences, Inc.’s revenue?
Lexington Biosciences, Inc. booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
OncoSec Medical Incorporated——Cannabiz Mobile, Inc.——Verde Science, Inc.——Thoughtful Brands Inc.——Greenwind Holdings Inc.——Poniard Pharmaceuticals, Inc.——Key facts
CEODonald Arthur McInnes
SectorHealthcare
IndustryMedical - Specialties
HeadquartersVancouver, BC
ExchangeOTC: LXGTF
Employees543
IPO date2017-07-19
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.